Leflunomide plus Methotrexate

ApprovedSmall molecule

Leflunomide plus Methotrexate is one of 5 small molecule programs targeting Polyarticular Juvenile Idiopathic Arthritis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polyarticular Juvenile Idiopathic ArthritisActive, not recruiting

Polyarticular Juvenile Idiopathic ArthritisApproved

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Polyarticular Juvenile Idiopathic Arthritis

#DrugCompanyPhaseTrials

Actemra

Roche

Phase 3

2 2

Orencia

Bristol-Myers Squibb

Phase 3

1 3

Remicade

OOrganon and Co

Phase 3

1 4

Mra(tocilizumab)

Roche

Phase 3

2 5

Leflunomide plus Methotrexate

BBangladesh Medical University

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Polyarticular Juvenile Idiopathic Arthritis1 trial

Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients

Completed·—·Phase 4·NCT07428551·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Leflunomide plus Methotrexate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leflunomide plus Methotrexate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leflunomide plus Methotrexate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bangladesh Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBangladesh Medical University

Leflunomide plus Methotrexate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Polyarticular Juvenile Idiopathic Arthritis1 trial

References

Drug Info

Quick Facts

Related News